Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Oncology

Staging and Risk: Understanding the Roadmap

At a Glance

Staging Langerhans cell histiocytosis (LCH) determines the best treatment based on how much of the body is affected. It is categorized as single-system or multisystem, with doctors checking specific risk organs like the liver, spleen, and bone marrow to guide therapy intensity.

LCH is not a “one-size-fits-all” disease. To determine the best treatment, doctors use a process called staging to categorize the disease based on where it is in the body and how much it might interfere with vital organ functions [1][2]. Understanding these categories helps clarify why some patients receive very mild treatment while others require intensive therapy.

Single-System vs. Multisystem LCH

The first step in staging is deciding how many “systems” are involved:

  • Single-System (SS-LCH): The disease is found in only one organ or system. The most common example is a single bone lesion or a rash limited to the skin [3][4]. These cases often have an excellent prognosis and may require minimal treatment [5].
  • Multisystem (MS-LCH): The disease is found in two or more different organ systems (for example, the skin and the bones, or the liver and the lungs) [4].

The “Risk Organs” (RO)

When a patient has Multisystem LCH, the most important question is whether the Risk Organs are involved. These are the organs that, if compromised, can make the disease much more serious [6].

  • The Liver: Involvement is checked via blood tests (for high bilirubin or low albumin) and imaging like ultrasound [6][7].
  • The Spleen: Doctors check for an enlarged spleen during physical exams or on scans [7].
  • The Hematopoietic System (Bone Marrow): This is checked by looking at blood counts. Low levels of red blood cells, white blood cells, or platelets can indicate the LCH is interfering with blood production [6].
    (Note: The gastrointestinal (GI) tract can also be involved. While rare, it is medically significant and mimics inflammatory bowel disease, requiring careful monitoring [8].)

Patients with Risk Organ involvement (RO+) require more intensive chemotherapy to protect these vital functions [5][1].

CNS-Risk Lesions: Areas Requiring Extra Monitoring

Even if LCH is not in a “Risk Organ,” it may be in a CNS-risk location. These are bone lesions found in the face and skull that sit very close to the brain and the pituitary gland [9].

  • Locations: These include the orbits (eye sockets), the temporal bones (the area around the ears), and the sphenoid or ethmoid bones (the base of the skull) [9][10].
  • The Risks: While these lesions are usually not life-threatening, they are “red flags” for long-term complications. They are associated with a higher risk of Central Diabetes Insipidus (CDI)—a permanent condition affecting water balance—and Neurodegenerative LCH (ND-LCH), a rare, progressive condition that can affect balance and coordination [9][11][12].

How Doctors Stage the Disease

To figure out where you or your child fits on this spectrum, the medical team will typically perform:

  1. Imaging: A PET/CT scan or a Skeletal Survey (a series of X-rays) to find all bone lesions [13][14].
  2. MRI: A specialized MRI of the brain and pituitary gland to look for thickening of the pituitary stalk or other “CNS-risk” signs [15][16].
  3. Blood Work: Comprehensive tests to evaluate liver function and bone marrow health [6].

Knowing the staging—for example, “Multisystem without Risk Organ involvement”—gives you a roadmap for what to expect during treatment and what specific “late effects” your team will be watching for in the years to come.

Back to Home

Common questions in this guide

What is the difference between single-system and multisystem LCH?
Single-system LCH means the disease is found in only one organ or system, such as a single bone lesion or an isolated rash. Multisystem LCH is found in two or more different organ systems, which changes how the medical team approaches treatment.
What are the 'risk organs' in LCH?
The primary risk organs in LCH are the liver, spleen, and bone marrow (hematopoietic system). When LCH involves these organs, it can compromise their vital functions and generally requires more intensive chemotherapy to treat.
Why are bone lesions in the skull or face considered 'CNS-risk'?
CNS-risk lesions are specific LCH bone lesions located in the face and skull, close to the brain and pituitary gland. While not usually life-threatening themselves, they require close monitoring because they increase the risk for long-term neurological issues and Central Diabetes Insipidus.
What tests are used to stage LCH?
Medical teams use imaging like PET/CT scans or skeletal surveys to find bone lesions, and specialized brain MRIs to look for CNS-risk signs. Comprehensive blood tests are also used to evaluate bone marrow health and liver function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the staging scans, is the disease Single-System or Multisystem LCH?
  2. 2.Are there any signs of involvement in the 'Risk Organs' (liver, spleen, or bone marrow) in the blood work or imaging?
  3. 3.Are any of the bone lesions located in 'CNS-risk' areas, such as the orbits, temporal bones, or skull base?
  4. 4.Is the 'bright spot' in the pituitary gland visible on the MRI, and what does that mean for the risk of diabetes insipidus?
  5. 5.How does this specific classification (e.g., MS-RO+) change the intensity of the treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis.

    Ferrell J, Sharp S, Kumar A, et al.

    Pediatric blood & cancer 2021; (68(4)):e28891 doi:10.1002/pbc.28891.

    PMID: 33442960
  2. 2

    FDG PET-CT in pediatric Langerhans cell histiocytosis.

    Jessop S, Crudgington D, London K, et al.

    Pediatric blood & cancer 2020; (67(1)):e28034 doi:10.1002/pbc.28034.

    PMID: 31599488
  3. 3

    Langerhans cell histiocytosis (LCH). Overview of symptoms of LCH, which may lead the patients to any of these medical specialists.

    Adam Z, Pour L, Tomíška M, et al.

    Vnitrni lekarstvi 2022; (68(E-2)):11-21.

    PMID: 36208940
  4. 4

    Hydroxyurea: a new old therapy for Langerhans cell histiocytosis.

    Zinn DJ, Grimes AB, Lin H, et al.

    Blood 2016; (128(20)):2462-2465 doi:10.1182/blood-2016-06-721993.

    PMID: 27688802
  5. 5

    Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis.

    Monsereenusorn C, Rodriguez-Galindo C

    Hematology/oncology clinics of North America 2015; (29(5)):853-73.

    PMID: 26461147
  6. 6

    Pediatric Langerhans Cell Histiocytosis: An Aggressive Presentation.

    Suthersan S, Ong FM, Maruthamuthu T, et al.

    Cureus 2022; (14(6)):e25684 doi:10.7759/cureus.25684.

    PMID: 35812621
  7. 7

    [Status of Langerhans cell histiocytosis in children and adults].

    Kudo K

    [Rinsho ketsueki] The Japanese journal of clinical hematology 2019; (60(9)):1308-1316 doi:10.11406/rinketsu.60.1308.

    PMID: 31597857
  8. 8

    Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report.

    Liu Y, Chen Z, Wang L, Li B

    Pathology oncology research : POR 2024; (30()):1611705 doi:10.3389/pore.2024.1611705.

    PMID: 38605931
  9. 9

    Neurodegeneration in Langerhans Cell Histiocytosis: beyond a Sequela.

    Santa-María López V, Gutiérrez-Carrasco I, Pérez-Martínez A, et al.

    Anales de pediatria 2026; (104(2)):504058 doi:10.1016/j.anpede.2026.504058.

    PMID: 41651751
  10. 10

    A case of multisystem Langerhans cell histiocytosis presenting as central diabetes insipidus.

    Nicholas PD, Garrahy I

    Journal of community hospital internal medicine perspectives 2019; (9(6)):515-517 doi:10.1080/20009666.2019.1698231.

    PMID: 32002162
  11. 11

    Paediatric Langerhans Cell Histiocytosis Disease: Long-Term Sequelae in the Hypothalamic Endocrine System.

    Vaiani E, Felizzia G, Lubieniecki F, et al.

    Hormone research in paediatrics 2021; (94(1-2)):9-17 doi:10.1159/000517040.

    PMID: 34167121
  12. 12

    CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

    McClain KL, Picarsic J, Chakraborty R, et al.

    Cancer 2018; (124(12)):2607-2620 doi:10.1002/cncr.31348.

    PMID: 29624648
  13. 13

    18F-Fluorodeoxyglucose PET/CT in Langerhans cell histiocytosis: spectrum of manifestations.

    Agarwal KK, Seth R, Behra A, et al.

    Japanese journal of radiology 2016; (34(4)):267-76 doi:10.1007/s11604-016-0517-7.

    PMID: 26759026
  14. 14

    18F-FDG PET/CT in follow-up evaluation in pediatric patients with Langerhans histiocytosis.

    Garcia JR, Riera E, Bassa P, et al.

    Revista espanola de medicina nuclear e imagen molecular 2017; (36(5)):325-328 doi:10.1016/j.remn.2017.01.007.

    PMID: 28262495
  15. 15

    Isolated Langerhans cell histiocytosis in the hypothalamic-pituitary region: a case report.

    Zhou W, Rao J, Li C

    BMC endocrine disorders 2019; (19(1)):143 doi:10.1186/s12902-019-0474-0.

    PMID: 31856773
  16. 16

    Langerhans' cell histiocytosis of the temporal bone in an adult with central diabetes insipidus.

    Allen A, Matrova E, Ozgen B, et al.

    Radiology case reports 2019; (14(7)):847-850 doi:10.1016/j.radcr.2019.03.040.

    PMID: 31080537

This page provides educational information about LCH staging and risk categories. It does not replace professional medical advice or the interpretation of diagnostic scans by your oncology team.

Get notified when new evidence is published on Langerhans cell histiocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.